Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-5 BI 764532 dose-selection trial in relapsed/refractory extensive-stage small cell lung cancer and other neuroendocrine carcinomas
2023-504247-13-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 2, open-label trial of obrixtamig in small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (EPNEC) and large cell neuroendocrine carcinoma (LCNEC) (3 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Objective response, Treatment-emergent adverse events and 1 more. Planned start Oct 2023; status: authorised.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)extrapulmonary neuroendocrine carcinoma (EPNEC)large cell neuroendocrine carcinoma (LCNEC)
Beyond the preview
Go deeper on 2023-504247-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504247-13-00.